← Catalogus
Serie

Road to Cure

9 delen · door M.E.H.M Hoef, M.E.H.M. Hoef, M.E.H.M. Van Hoef · 2000–2007
Leesvolgorde
  1. Multicenter phase I-II study of intensified induction and consolidation chemotherapy with autologous PBPC infusion followed by non-myeloablative HLA-identical sibling transplant for early metastatic breast cancer. (2000)
  2. Dose dense induction chemotherapy, two semi-high-dose conditioning autologous peripheral blood progenitor cell transplant and a non-myeloablative reduced intensity conditioning allogeneic stem cell transplants in patients with and without donor for lymph node 4+ and to the bone marrow metastasized breast cancer (2007)
  3. Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for lymphoma. (2007)
  4. Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for multiple myeloma. (2007)
  5. Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for neuroblastoma. (2007)
  6. Dose intensive induction, consolidation by a cytarabin containing regimen and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for acute myeloid leukemia. (2007)
  7. Intensive and/or dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or equivalent in acute leukemia followed by an non-myeloablative reduced intensity conditioning allogeneic transplants in patients with donor compared to patients without donor (AML, ALL, CML, HD, NHL, neuroblastoma) (2007)
  8. Protocol for CML until molecular complete remission has been obtained followed by a non-myeloablative reduced intensity conditioning allogeneic transplant within 12 months from diagnosis. (2007)
  9. Multicenter phase I-II project for studying treatment by intensive dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or an equivalent in acute leukemia followed by an allogeneic non-myeloablative transpla7
Multicenter phase I-II study of intensified induction and consolidation chemotherapy with autologous PBPC infusion followed by non-myeloablative HLA-identical sibling transplant for early metastatic breast cancer.
M.E.H.M Hoef
Multicenter phase I-II study of intensified induction and consolidation chemotherapy with autologous PBPC infusion followed by non-myeloablative HLA-identical sibling transplant for early metastatic breast cancer.
M.E.H.M Hoef
Losbladig · 2000
Dose dense induction chemotherapy, two semi-high-dose conditioning autologous peripheral blood progenitor cell transplant and a non-myeloablative reduced intensity conditioning allogeneic stem cell transplants in patients with and without donor for lymph node 4+ and to the bone marrow metastasized breast cancer
M.E.H.M. Hoef
Dose dense induction chemotherapy, two semi-high-dose conditioning autologous peripheral blood progenitor cell transplant and a non-myeloablative reduced intensity conditioning allogeneic stem cell transplants in patients with and without donor for lymph node 4+ and to the bone marrow metastasized breast cancer
M.E.H.M. Hoef
Losbladig · 2007
Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for lymphoma.
M.E.H.M. Van Hoef
Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for lymphoma.
M.E.H.M. Van Hoef
Losbladig · 2007
Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for multiple myeloma.
M.E.H.M. Hoef
Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for multiple myeloma.
M.E.H.M. Hoef
Losbladig · 2007
Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for neuroblastoma.
M.E.H.M Hoef
Dose dense induction, followed by two semi-high-dose conditioning autologous transplants and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for neuroblastoma.
M.E.H.M Hoef
Losbladig · 2007
Dose intensive induction, consolidation by a cytarabin containing regimen and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for acute myeloid leukemia.
M.E.H.M. Van Hoef
Dose intensive induction, consolidation by a cytarabin containing regimen and a non-myeloablative reduced intensity conditioning allogeneic transplants in patients with and without donor for acute myeloid leukemia.
M.E.H.M. Van Hoef
Losbladig · 2007
Intensive and/or dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or equivalent in acute leukemia followed by an non-myeloablative reduced intensity conditioning allogeneic transplants in patients with donor compared to patients without donor (AML, ALL, CML, HD, NHL, neuroblastoma)
M.E.H.M. Hoef
Intensive and/or dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or equivalent in acute leukemia followed by an non-myeloablative reduced intensity conditioning allogeneic transplants in patients with donor compared to patients without donor (AML, ALL, CML, HD, NHL, neuroblastoma)
M.E.H.M. Hoef
Losbladig · 2007
Protocol for CML until molecular complete remission has been obtained followed by a non-myeloablative reduced intensity conditioning allogeneic transplant within 12 months from diagnosis.
M.E.H.M. Hoef
Protocol for CML until molecular complete remission has been obtained followed by a non-myeloablative reduced intensity conditioning allogeneic transplant within 12 months from diagnosis.
M.E.H.M. Hoef
Losbladig · 2007
Multicenter phase I-II project for studying treatment by intensive dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or an equivalent in acute leukemia followed by an allogeneic non-myeloablative transpla7
M.E.H.M. van Hoef
Multicenter phase I-II project for studying treatment by intensive dose dense induction chemotherapy, an autologous transplant strategy consisting of two semi-high-dose autologous transplants or an equivalent in acute leukemia followed by an allogeneic non-myeloablative transpla7
M.E.H.M. van Hoef
Losbladig